Immunexpress, Inc.

Immunexpress develops rapid diagnostic technology for sepsis detection based on immune response biomarker analysis. The company's flagship product, SeptiCyte® RAPID, is a fully automated cartridge compatible with the Biocartis Idylla™ platform that quantifies and analyzes gene expression from whole blood samples to diagnose sepsis in suspected patients within one hour—compared to traditional testing methods that require 24–48 hours and produce actionable results in only 20% of cases. SeptiCyte® RAPID delivers clinically actionable results for 100% of tested patients. The technology addresses a critical clinical need: sepsis remains the leading cause of death in hospitals globally (11 million deaths annually among 49 million cases), yet early detection is hampered by inadequate diagnostic tools. By enabling rapid diagnosis, Immunexpress's solution aims to reduce mortality rates, shorten hospital stays, and lower healthcare costs. The company targets acute care hospitals and clinicians managing suspected sepsis cases across intensive care and emergency departments. Manufacturing and delivery are achieved through partnership with Biocartis, leveraging their Idylla™ automated molecular analysis platform.